Adzenys ER Oral Suspension Launched for ADHD
Neos Therapeutics announced the availability of Adzenys ER (amphetamine) Extended-Release Oral Suspension for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged ≥6 years.
Adzenys ER oral suspension, approved in September 2017, does not require reconstitution or refrigeration. The once-daily medication uses the same modified-release drug delivery technology seen in Adzenys XR-ODT (amphetamine) Extended-Release Orally Disintegrating Tablets. Adzenys ER and Adzenys XR-ODT are considered bioequivalent to Adderall XR.
Amphetamines are non-catecholamine sympathomimetic amines with central nervous system (CNS) stimulant activity. The exact mode of therapeutic action in ADHD is unknown. Other ADHD extended-release medications from Neos include Adzenys XR-ODT and Cotempla XR-ODT (methylphenidate) extended-release orally-disintegrating tablets.
Adzenys ER is a CII controlled substance. It is available as 1.25mg/mL orange-flavored oral suspension in 450mL bottles.
For more information call (888) 319-1789 or visit NeosTx.com.